Lemborexant to Prevent Post-operative Delirium in Cardiac Surgery Patients
Key facts
- Who runs it
- University of British Columbia
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 60 people, planned
- Started
- 1 May 2025
- Expected to end
- 30 Apr 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Lemborexant 5 mg
- Control (placebo) group
- Record updated
- 23 April 2025
Who can take part
- Age
- 61 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Admitted to hospital following open cardiac surgery through midline sternotomy
Who cannot take part
- ● Known severe obstructive sleep apnea diagnosed by polysomnography or STOPBANG score > 5; Periodic limb movement disorder or restless legs syndrome; Narcolepsy; Somnolence (Pasero Opioid Sedation Scale (POSS) >2); Current alcohol or substance use disorder as defined by the DSM-V; Patient already taking moderate or strong CYP3A inhibitors; Frequent use of medications for insomnia defined as >4 days per week; Liver failure (Child-Pugh score B or C); Renal failure (eGFR<30 ml/min/1.73 m2); Pre-existing delirium (ICDSC score >3 or CAM/CAM-ICU positive) at time of consent; BMI>40 kg/m2; Known allergy or hypersensitivity to study drug; Inability to communicate in English
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Post-operative delirium is a common complication following cardiac surgery and is associated with increased 1 year mortality. Currently there are no drug therapies to prevent delirium. Orexin is a neuromodulator thought to play an important role in disordered sleep, one of the instigators of delirium. Lembrorexant is an orexin antagonist, originally approved for sleep, that may also reduce the incidence of delirium. The Investigators propose a pilot study to determine the feasibility of a randomized controlled trial comparing Lembrorexant to placebo in patients following cardiac surgery in reducing the incidence of delirium, and improving sleep.
The 2 groups in the trial
- InterventionTreatment being tested
The intervention arm will receive the study drug, Lemborexant 5mg, daily for 7 days post-operatively while in hospital.
Treatment: Lemborexant 5 mg
- ControlPlacebo, for comparison
The Control arm will receive the placebo study drug daily for 7 days post-operatively while in hospital.
Treatment: Control (placebo) group
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Randomized Trial of Lemborexant for the Prevention of Delirium After Cardiac Surgery (PROTEX): A Pilot Study
- Record updated
- 23 April 2025